Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2012
06/19/2012CA2471043C Stable surfactant compositions for suspending components
06/19/2012CA2390898C Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues
06/14/2012WO2012078004A2 Composition comprising fermented tea extracts for reducing lipid level
06/14/2012WO2012076966A1 Substituted thieno [3,4-b] pyrazine compounds
06/14/2012WO2012076739A1 Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies
06/14/2012WO2012076430A1 Triazolopyridine compounds
06/14/2012WO2012046945A3 Pharmaceutical and food composition for preventing or treating diabetes or obesity
06/14/2012WO2012019188A3 Methods and compositions for the inhibition of fructokinase
06/14/2012WO2011140135A9 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
06/14/2012WO2011042765A8 Inorganic salt complexes of vildagliptin
06/14/2012US20120149780 Method of Use of Vitamin K as Energy Enhancer in Diverse Disease States
06/14/2012US20120149778 Compounds
06/14/2012US20120149774 Compositions and methods for nutrient delivery
06/14/2012US20120149769 Thiocarbonates as Anti-Inflammatory and Antioxidant Compounds Useful For Treating Metabolic Disorders
06/14/2012US20120149760 Disabling autophagy as a treatment for lysosomal storage diseases
06/14/2012US20120149759 Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
06/14/2012US20120149736 Enzyme inhibitors
06/14/2012US20120149734 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
06/14/2012US20120149732 Multifunctional linkers and methods for the use thereof
06/14/2012US20120149729 Metalloenzyme inhibitor compounds
06/14/2012US20120149728 Novel fumarate salts of a histamine h3 receptor antagonist
06/14/2012US20120149723 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
06/14/2012US20120149718 Amido Compounds
06/14/2012US20120149704 Disubstituted benzamide derivatives as glucokinase (gk) activators
06/14/2012US20120149703 Aza-substituted spiro derivatives
06/14/2012US20120149701 Certain chemical entities, compositions and methods
06/14/2012US20120149700 2-cyanophenyl fused heterocyclic compounds, and compostions and uses thereof
06/14/2012US20120149696 Ethylene diamine modulators of fatty acid hydrolase
06/14/2012US20120149693 Therapeutic compounds
06/14/2012US20120149683 Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
06/14/2012US20120149682 Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
06/14/2012US20120149681 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
06/14/2012US20120149680 Kinase inhibitors
06/14/2012US20120149673 Inhibitors of store operated calcium release
06/14/2012US20120149664 Transdermal Composition of Phosphatidylcholine and Method for Producing Same
06/14/2012US20120149655 Use of jasmonate to treat bladder dysfunction
06/14/2012US20120149652 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
06/14/2012US20120149648 Therapeutic peptidomimetic macrocycles
06/14/2012US20120149640 Peptides modulating the activity of igf-1 and the applications of said peptides
06/14/2012US20120149639 Use of a dpp-iv inhibitor to reduce hypoglycemic events
06/14/2012US20120149637 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
06/14/2012US20120149636 Modified Leptin Polypeptides and Their Uses
06/14/2012US20120149635 Treatment for obesity
06/14/2012US20120149634 Compounds and methods for treating bone disorders and controlling weight
06/14/2012US20120149633 Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom
06/14/2012US20120148692 Novel herbal formulation for the prevention and management of type-2 diabetes mellitus and vascular complications associated with diabetes
06/14/2012US20120148685 Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
06/14/2012US20120148684 Methods useful in the treatment of bone resorption diseases
06/14/2012US20120148673 Peptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
06/14/2012US20120148654 Method and system for a photoresist-based immunoisolative microcontainer with nanoslots defined by nanoimprint lithography
06/14/2012US20120148642 Multi-domain amphipathic helical peptides and methods of their use
06/14/2012US20120148603 Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
06/14/2012US20120148588 Methods for increasing thermogenic adipocytes
06/14/2012US20120148582 Engineered anti-il-23r antibodies
06/14/2012US20120148581 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
06/14/2012US20120148569 Picrorhiza kurroa extract for prevention, elimination and treatment of infection diseases
06/14/2012US20120148565 Increasing lifespan by modulation of wwp-1 and ubc-18
06/14/2012US20120148558 Delivery of Therapeutic Compounds to the Brain and Other Tissues
06/14/2012US20120148551 Marrow stem cell and pancreatic beta cell fusion cell useful for the treatment of diabetes
06/14/2012US20120148540 Proliferated cell lines and uses thereof
06/14/2012US20120148527 TNF Superfamily Fusion Proteins
06/14/2012US20120148493 Composite Materials Loaded with Therapeutic and Diagnostic Agents Comprising Polymer Nanoparticles and Polymer Fibers
06/14/2012DE102010053748A1 Composition, useful to treat and/or prevent obesity, comprises a specified range of hydoxycarboxylic acid, protein powder, sodium bicarbonate and magnesium carbonate
06/14/2012CA2824619A1 Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies
06/14/2012CA2816829A1 Triazolopyridine compounds
06/13/2012EP2463290A1 Thienooxazepine derivative
06/13/2012EP2463282A1 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
06/13/2012EP2463279A1 Amide derivative
06/13/2012EP2462943A1 Dipeptidyl peptidase-4 inhibitor
06/13/2012EP2462229A2 Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
06/13/2012EP2462121A1 Derivatives of 2h pyridazin- 3 -ones, their preparation and their use as scd-1 inhibitors
06/13/2012EP2461683A1 Bicyclic aryl sphingosine 1-phosphate analogs
06/13/2012EP2461681A1 Use of melanocortins to treat dyslipidemia
06/13/2012EP2399927A9 Novel compound, phosphorylation inhibitor, insulin resistance improving agent, agent to prevent or to treat diabetes, and screening method
06/13/2012EP2243490B1 Insulin nasal powder inhalation
06/13/2012EP2215068B1 Antidiabetic tricyclic compounds
06/13/2012EP2001841B1 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
06/13/2012EP1979311B1 Phenoxy acetic acids as ppar delta activators
06/13/2012EP1836180B1 Sulfonyl pyrrolidines, method for producing the same and their use as drugs
06/13/2012EP1495053B1 Angiopoietin-2 and angiopoietin-1 specific binding agents
06/13/2012EP1414471B1 Therapeutic agents comprising pro-apoptotic proteins
06/13/2012EP0451216B2 Humanized immunoglobulins and their production and use
06/13/2012CN1390126B Use of selective estrogen receptor modulator in preparing medicine for treating obesity or reducing risk of development of obesity
06/13/2012CN102498103A Pyrazine carboxamides as inhibitors of DGAT1
06/13/2012CN102498099A HSL inhibitors useful in the treatment of diabetes
06/13/2012CN102498091A Glycine compound
06/13/2012CN102497885A Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
06/13/2012CN102497881A Combination therapy for the treatment of diabetes
06/13/2012CN102497873A Compositions and methods for increasing lifespan and health span
06/13/2012CN102492654A Kit for separating human umbilical cord blood stem cells and its using method
06/13/2012CN102492594A Bamboo juice wine and preparation method thereof
06/13/2012CN102492051A Polygonatum odoratum deep processing and comprehensive utilization process
06/13/2012CN102491978A Method for preparing natural pigments, polysaccharide and saponin by utilizing disused asparagus resources
06/13/2012CN102491969A Heteroaromatic quinoline compounds
06/13/2012CN102491966A Piperonyl pentylene acid sodium and application on blood lipid reduction thereof
06/13/2012CN102488970A Electromagnetic therapeutic apparatus and matched physical therapy liquid thereof
06/13/2012CN102488889A Caspofungin preparation with low impurity content and preparation method and application thereof
06/13/2012CN102488846A Medicinal composition for treating diabetes mellitus
06/13/2012CN102488840A Blood sugar reducing preparation and preparation method thereof
06/13/2012CN102488839A Extraction method for saponins of rhizoma polygonati
1 ... 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 ... 1298